...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Molecular Sciences >Clinical Application of Circulating Tumour Cells in Prostate Cancer: From Bench to Bedside and Back
【24h】

Clinical Application of Circulating Tumour Cells in Prostate Cancer: From Bench to Bedside and Back

机译：循环肿瘤细胞在前列腺癌中的临床应用：从实验台到床边再到背部

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Prostate cancer is the most common cancer in men worldwide. To improve future drug development and patient management, surrogate biomarkers associated with relevant outcomes are required. Circulating tumour cells (CTCs) are tumour cells that can enter the circulatory system, and are principally responsible for the development of metastasis at distant sites. In recent years, interest in detecting CTCs as a surrogate biomarker has ghiiukjrown. Clinical studies have revealed that high levels of CTCs in the blood correlate with disease progression in patients with prostate cancer; however, their predictive value for monitoring therapeutic response is less clear. Despite the important progress in CTC clinical development, there are critical requirements for the implementation of their analysis as a routine oncology tool. The goal of the present review is to provide an update on the advances in the clinical validation of CTCs as a surrogate biomarker and to discuss the principal obstacles and main challenges to their inclusion in clinical practice.
机译：前列腺癌是全世界男性中最常见的癌症。为了改善未来的药物开发和患者管理，需要与相关结果相关的替代生物标志物。循环肿瘤细胞（CTC）是可以进入循环系统的肿瘤细胞，主要负责远处转移的发展。近年来，人们对检测CTC作为替代生物标记物的兴趣不断增长。临床研究表明，血液中高水平的四氯化碳与前列腺癌患者的疾病进展有关。然而，它们对监测治疗反应的预测价值尚不清楚。尽管在CTC临床开发中取得了重要进展，但仍需要将其分析作为常规的肿瘤学工具来实施。本综述的目的是提供有关作为替代生物标志物的四氯化碳的临床验证进展的最新信息，并讨论将其纳入临床实践的主要障碍和主要挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号